HIV Prevention Trials Network

Clarification Memorandum # 04 to:

HPTN 059, Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel, Version# 2.0, Dated 13 March 2006

IND #55, 690

Date of Clarification Memorandum: 18 June 2007

Section 1: Summary of Clarifications and Rationale

The procedures clarified in this memorandum have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. IRB approval of this Clarification Memorandum is not required by the sponsor; however, investigators may submit the clarification memo to the IRBs/ECs overseeing the study at their site for their information.

This clarification memo is official HPTN 059 protocol documentation. It is effective immediately. A copy of this memo must be retained in each study site's Essential Documents file for HPTN 059.

No change in the informed consent form are necessitated by or included in this Clarification Memo.

The primary goal for this clarification memo is:

To remove any redundant and/or irrelevant sections from Section 5.9, entitled "Follow Up Procedures for Participants Who Discontinue Study Product". Subsection 5.9.3 "Participants Who Become Infected with Hepatitis B" has been deleted because these participants will continue study gel use and follow all protocol procedures after Hepatitis B diagnosis; therefore this subsection is not relevant under Section 5.9. Subsections 5.9.4 "Participants Who Voluntary Discontinue Study Gel" and 5.9.5 "Participants Who Discontinue Study Gel Use Permanently (as advised by study staff)" have been deleted because the modified procedures identified in these subsections have already been discussed in Section 5.9, therefore these sections are redundant.

Section 3: Implementation

Text to be deleted is noted below by ~~strikethrough~~; text to be added is noted below in **bold.**

1. Section 5.9 (Page 39 of 65), the following will be deleted:

~~5.9.3 Participants Who Become Infected With Hepatitis B~~

~~Participants who are incidentally found to be acutely infected with hepatitis B during the course of the study will not be withdrawn from the study. All protocol specified procedures will continue and the infection will be managed in accordance with current clinical practice at each site. Hepatitis B symptoms will be managed in accordance with conventional clinical practice.~~

~~If the participant provides written informed consent, she may be followed according to protocol evaluations for CHBV participants.~~

~~5.9.4 Participants Who Voluntarily Discontinue Study Gel:~~

~~All protocol-specified study procedures will continue except:~~

- ~~Provision of study gel~~

~~5.9.5 Participants Who Discontinue Study gel Use Permanently (as advised by study staff):~~

~~All protocol-specified study procedures will continue except:~~

- ~~Provision of study gel~~
- ~~PK assessments~~